• A New Circular Solution: Polycarbin and Westfall Technik are Collaborating to Bring Circular Materials to the Biomedical Industry

    “Our goal is to set ourselves apart in the Sustainability arena by leveraging our integrated technology solution to deliver products with high levels of recycled content and drive the circular economy. We have achieved up to 100% recycled content inclusion levels for our customers in the Consumer Products Goods and Food & Beverage areas, and with this partnership will be the first company to introduce recycled content in the life science and biomedical space,” says Allison Lin, VP of Sustainability at Westfall-Technik. “We welcome the opportunity to help both CPG and Medical customers run high levels of recycled content for new and existing products.” Using a system that leverages low-cost front-end segregation and a waste analytics platform, Polycarbin is positioned to capture and repurpose valuable scientific plastics. Polycarbin’s services provide more cost-effective and environmentally responsible waste management solutions to research labs, biopharma, and clinical labs while closing the loop on the biomedical plastic life cycle. “Polycarbin is transforming resource management in the health sciences,” says James O’Brien, Co-CEO of Polycarbin. “We are incredibly proud to be partnering with an industry leader like Westfall Technik that has a track record of championing circular economy innovations. Utilizing our waste diversion platform, Polycarbin is helping our clients across biopharma, healthcare, and research to reduce the carbon footprint of innovation.” Westfall Technik is a global holding company which provides highly-productive plastics manufacturing solutions to the medical, consumer packaging and consumer goods industries. Westfall Technik’s competitive advantages include modern automated systems, correlative molding processes, and effective industry 4.0 concepts. Brand owners can expect high quality products at an excellent value, a fast response for decreased time-to-market, 100% inspection and traceability from pellet to pallet, supply chain security compliance, and reliability from a trustworthy team. Westfall Technik recently joined the Association of Plastic Recycler’s Demand Champions Program and the Ellen MacArthur Foundation’s Global Commitment for a New Plastics Economy.

  • Jones Healthcare Group Invests in New High-Performance Uhlmann Blister Packaging Line

    Jones Healthcare Group, a market leader in advanced packaging and medication dispensing solutions, today announces a significant investment in its packaging services offering including a new, fully integrated two-lane Uhlmann blister packaging line. The highly automated equipment will enhance the firm’s capacity to manage demand surges and unique blister combinations, as more complex pharmaceutical dosage forms and regimes evolve clinically and commercially. “Our new line offers the highest quality, productivity and flexibility for blister packaging in a Health Canada and FDA-registered facility, including a full serialization and aggregation solution for prescription medicines,” says Marty Quesnel, Senior Vice President – Packaging Services at Jones. “We’re proud to work with world-class pharmaceutical equipment manufacturer Uhlmann to expand our offering with state-of-the-art technology.” Fully compliant with the Drug Supply Chain Security Act (DSCSA), the automated line includes a two-lane B 1440 blister machine and C 2305 cartoner, as well as end-of-line stretch-wrapping and bundling. The equipment is capable of multi-product blistering for more complex dosing regimens, and multi-product cartoning for combination packs. The line also integrates a wide range of forming and lidding films such as PVC, Alu+Alu and child-resistant formats, with compatibility for multiple products and carton format. “Now more than ever, our pharmaceutical customers look to us to manage more of their packaging process. This helps them meet unprecedented demand for over-the-counter headache, cold and other respiratory products for our communities, while also pivoting resources to support the pandemic response,” adds Ron Harris, President & CEO at Jones. “Our ongoing investment in services and capabilities ensures healthcare companies can continue to count on us as a reliable, resilient supply chain partner.” The new line will be installed at the company’s Brampton, Canada facility and is anticipated to be operational early next year.

  • BIC Uses Plastic Packaging Materials to Produce PPE

    As COVID-19 cases continue to rise in parts of the U.S., states are still struggling to secure the volume of PPE necessary to keep up with the spread of the virus. To help arm frontline workers, BIC North America will be producing 2,000 medical-grade face shields per day at its factory in Milford, Conn. The face shields, approved by the FDA as Level 1 medical devices, are all made with materials typically used in packaging (the plastic) or would otherwise be scrap from materials used in the lighters. In addition, the shields are designed so the plastic can be removed and sterilized by the hospitals, rather than disposed of. To date, BIC has received requests for nearly 25,000 shields from a number of Connecticut hospitals (including Waterbury and Norwalk), nursing homes, police/fire departments, AMR (the ambulance/first responders), and others. “As a global company with thousands of team members in communities around the world, we strongly believe that we have the opportunity—and the responsibility—to make a meaningful contribution to our communities during this global health crisis,” says Gonzalve Bich, BIC CEO. “Our thoughts are with all those who have been impacted by COVID-19. We send our heartfelt gratitude to all the doctors, nurses, paramedics, factory workers, and first responders putting themselves on the frontlines to protect our communities and economies.” Other donations from BIC include the following: . Eighty-seven thousand razors were donated through Amazon’s Goods for Good program, which allows non-profits to place free orders with free shipping to those they serve, including community service organizations, veterans groups, food banks, and housing organizations. BIC has committed up to 200,000 razors through this program, but Amazon wants to order them in batches and will replenish when inventory diminishes. · More than 7,000 multipurpose lighters were donated to two non-profit community organizations, including one that supports military families. More than 28,000 stationery products and 4,000 shavers were donated to the Respiratory Care Department of the Henry Ford Wyandotte Hospital in Michigan. BIC’s efforts also extend globally. At the end of March, BIC began producing face shields at its lighter facility in Redon, France. The team there is producing 3,000 per day using raw materials the company already has in its possession, including packaging plastic, rubber, and more. The first batch was donated to the local hospital and police force. Production of these and other face shields has expanded to facilities in Brazil, Greece, and Tunisia for local hospitals and government agencies.
  • International regulators align positions on phase 3 COVID-19 vaccine trials

    Medicines regulatory authorities from around the world have published a report today highlighting the outcomes of the second workshop on COVID-19 vaccine development that was convened under the umbrella of the International Coalition of Medicines Regulatory Authorities (ICMRA). The report describes the regulatory positions agreed by the meeting participants on two key topics: Data needed from laboratory, animal and human studies to allow initiation of phase 3 clinical trials for a COVID-19 vaccine; and Considerations for study design for phase 3 clinical trials.
  • EMA finalises opinion on presence of nitrosamines in medicines

    EMA’s human medicines committee (CHMP) has issued an opinion requiring companies to take measures to limit the presence of nitrosamines in human medicines as far as possible and to ensure levels of these impurities do not exceed set limits. The measures will ensure that nitrosamines are either not present or are present below levels identified to protect public health. Companies will be required to have appropriate control strategies to prevent or limit the presence of these impurities and, where necessary, improve their manufacturing processes.
  • Launch of public consultation on joint network strategy to 2025

    EMA and the Heads of Medicines Agencies (HMA) have developed a joint strategy for the next five years that is released for a two-month public consultation today. The draft strategy details how the European medicines agencies’ network can continue to enable the supply of safe and effective medicines that meet patients’ needs in the face of challenges posed by ever-accelerating developments in science, medicine, digital technologies, globalisation as well as emerging health threats, such as the COVID-19 pandemic.
  • Stevanato Group: Robotic Human-like Inspection Unit with AI-based Machine Learning

    Italy-based Stevanato Group, a producer of glass primary packaging and provider of integrated capabilities for drug delivery systems, is launching a modular, robotic inspection system that incorporates artificial intelligence with accrued machine learning capabilities at its Interphex Virtual Exhibition (July 15-17). The company’s Vision Robot Unit (VRU) is a reliable, autonomous module capable of automatically inspecting both cosmetic and particle properties without human intervention. The VRU’s island design, for which there is a patent pending, comprises a highly versatile “plug & play” concept with a freely configurable infeed and outfeed. It is also scalable, as multiple vision inspection units can be added to increase throughput. Its no glass-to-glass inspection process significantly mitigates the likelihood of product damage or breakage. Thanks to its AI technology, VRU is able to improve its inspection performance. The unit can quickly react to changing product characteristics – including active ingredient variations, differing fill levels and different containers–even throughout a single batch. It is also adaptive, exhibiting continuous learning from both production and operator stimuli. The result is an improvement in the reduction in both false rejects and, even more importantly, false positives. The VRU is suited to a broad array of applications in the pharma development and manufacturing landscape, including biotech products such as monoclonal antibodies (mAbs), vaccines and lyophilized drugs. Suitable for inspecting high-value products, the machine can be employed both in laboratory settings and for small batch production. The Vision Robot Unit is designed to meet emerging “smart factory” needs for a fully automated, flexible inspection system that enhances control process reliability. The unit includes automatic format changes, and the ability to gradually reduce set up times via image and data collection. The VRU is available with or without additional collaborative robots. Basic models offer particle inspection, while an optional add-on provides cosmetic inspection. Recent advancements in artificial intelligence promise to optimize pharma visual inspection processes, providing advanced analytical tools to identify and classify defective products with greater accuracy and robustness.

  • Aptar Beauty + Home Insights: How BBI Utilized Aptar’s Apollo Technology to Launch a New User Experience for Liquid Wrench

    This need for innovation in the aerosol market inspired Aptar Beauty + Home to create Apollo, the first pressurized accessory with a dual-spray option. Consumers now have the flexibility of choice in how they use the product with a simple twist and click. Blumenthal Brands Integrated (BBI) partnered with Aptar Beauty + Home to create a value-added delivery system for the automotive and industrial markets with the launch of Liquid Wrench Pro Penetrant and Lubricant featuring Apollo. The product features a narrow stream for tighter spaces and a wider spray for broader coverage.

  • How patient preferences are changing the design of drug delivery devices

    The following insights detail which preferences are driving the evolution of drug delivery device design. Adding ease to applications From using implants for contraception, to getting insulin injections at the dinner table, to using a wearable device to administer chemotherapy in the comfort of home, applications for drug delivery are largely being driven by patient preferences. Not only do these growing number of applications improve the patient experience, they also empower patients to play a more active role in managing their medications.2 Key takeaway: Drug delivery devices are increasingly designed to make compliance easier for patients, including new applications to help patients manage their medications on their own terms. Offering more flexibility in autoinjectors Produced by the millions, pens and autoinjectorscontinue to evolve due to a variety of factors, including the emergence of new biologics that require strict specifications for packaging and delivery. At the same time, patients are seeking more options to self-administer medications on a less-frequent basis, which is driving a wider variety of treatment options and releasing formulators from having to conform to <1mL dosage requirements.2 Key takeaway: Even in the well-defined pen and autoinjector market, we are seeing greater demand for ready-to-use drug delivery solutions that work with the latest biologic medications. Controlling where and when drugs are administered Even though prefilled syringe systems are still a primary packaging option, there is increasing demand for cartridge-based systems as dosage volumes increase and more patients administer their own medications. Using a prefilled, cartridge-based system empowers patients to take greater control by managing more of their care at a time and place that works for them, such as at home instead of a hospital.2 Key takeaway: Patients are looking for flexibility when it comes to larger-sized doses, making packaging of prefilled cartridges an increasingly popular option for drugs that require doses up to 10mL. Using technology to improve compliance Intelligent, wearable delivery systems offer another advantage for patients looking for more freedom and flexibility in their drug regimen. These devices use a smartphone connection to track and report injections to healthcare providers, sending helpful reminders to patients and alerts to their doctors when doses are missed. Wearable devices also offer other advantages over traditional autoinjectors, including greater flexibility to modify dosing and delivery times, as well as the ability to monitor patient adherence.1 Key takeaway: Packaging for drug delivery devices is becoming more user-centric, using technology to help patients minimize risk, improve compliance and support better health outcomes. Taking a holistic approach to drug delivery design As patients become more involved in managing their treatment plans and administering their medications, manufacturers are responding by applying human-centered design principles to injectables. Patients are demanding devices that are reliable and easy to use, with instructions that are easy to understand and applications that are as pain-free as possible.1 This more holistic approach helps to ensure the medication, device and patient experience work in harmony to support the drug delivery goals of patients and providers. Whether your project requires a single machine or a complex, large-scale integration, you need a partner with deep industry experience to help you increase patient safety while meeting FDA regulations. Let MGS solve your toughest challenges. We'll deliver a comprehensive solution that optimizes your production while minimizing your risk. Contact us at info@mgsmachine.com or request more information below.

  • Mondi safely packages QIAGEN’s SARS-CoV-2 test cartridge

    QIAGEN is a leading global provider of molecular Sample to Insight solutions. The company recently launched a syndromic test cartridge kit for the QIAstat-Dx Analyser System that can identify the SARS-CoV-2 coronavirus within an hour. Designed for use in hospitals, clinics and laboratories, the company’s new QIAstat-Dx syndromic testing platform comes in the form of a compact, modular, table-top device into which multi-chamber cartridges containing test samples are inserted for analysis. During times like these, flexibility in production is key to help support essential packaging needs in the medical industry. “Given that timely testing is a critical component of mitigating the spread of the pandemic, we stand ready to assist the medical community in any way we can. At Mondi Korneuburg, we adjusted our production planning in order to meet the increase in demand to support QIAGEN,” explains Eveline Wagner, Managing Director of Mondi Korneuburg. Mondi has an ongoing relationship with QIAGEN and is providing packaging for the test cartridges using a customised design. The white, unprinted, multilayer pouches consist of a polyester/aluminium/polyethylene (PET/Alu/PE) construction to provide the necessary protection from light and moisture so that the test kits are not compromised before they are used. We worked closely with QIAGEN to understand how best to ensure test kits are packaged safely. We are now ready to scale up production of this product and meet the new demands. Emilio Vidri, Sales Director Europe, Mondi Consumer Flexibles

  • Pages